AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings

Summary

AstraZeneca CEO Pascal Soriot stated that the company's AI applications in drug design have not yet produced clinical-stage candidates but may improve success rates in later-stage drug development and accelerate regulatory filings.